A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity

Ähnliche Einträge

• The role of incretin receptor agonists in the treatment of obesity
  von: Thomas Forst, et al.
  Veröffentlicht: (2024)
• Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures
  von: Amit Guy, et al.
  Veröffentlicht: (2024)
• Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
  von: Liang Zheng, et al.
  Veröffentlicht: (2025)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  von: Tommaso Bucci, et al.
  Veröffentlicht: (2025)
• Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
  von: Carel W. le Roux, et al.
  Veröffentlicht: (2024)